CGTX
COGNITION THERAPEUTICS INC
$1.21
+0.83%
$108.3M
No data for this timeframe.
Vol
Market Cap$108.3M
Cap SizeMicro Cap
Analyst ConsensusStrong Buy (90%)
Inst. Holders24 funds
Inst. Value$4.8M
Inst. Activity0 buys / 1 sells
Insider Activity3B / 0S
Insider Net $$32.5K
Reddit Sentiment77° Bullish
SEC Reports3
Press Releases7
Exchange Nasdaq·Sector Biological Products, (No Diagnostic Substances)·Inc. DE·CIK 0001455365·Prev Close $1.20
Recent Activity
Jun 5, 2026
short_volume
Short Volume: CGTX — 56.9% short (0.3M / 0.6M)
Short: 342,694 | Exempt: 26,566 | TRF Vol: 602,379 | Short Ratio: 56.9% | Off-exchange volume (dark
Jun 4, 2026
SEC
Cognition Therapeutics filed an 8-K furnishing an investor presentation for the Jefferies Global Healthcare Conference.
8-K — Impact 4/10
Jun 1, 2026
Press
Cognition Therapeutics announced its CEO will present at the Jefferies Global Healthcare Conference (June 4) and H.C. Wa
Impact 2/10
May 21, 2026
Press
Cognition Therapeutics held a productive FDA meeting on May 20, 2026, to discuss Phase 2 SHIMMER study results for zervi
Impact 6/10
May 7, 2026
SEC
Cognition Therapeutics reported Q1 2026 net loss of $4.6M ($0.05/share), narrower than the $8.5M loss in Q1 2025, driven
8-K — Impact 5/10
May 1, 2026
Insider
Doyle John Brendan surrendered for taxes 8,567 shares
Chief Financial Officer @ $1.28 ($11.0K)
Apr 20, 2026
SEC
Two C-suite executives at Cognition Therapeutics (CGTX) — the CEO and Chief Medical Officer — purchased shares in the op
CLUSTER — Impact 5/10
Apr 16, 2026
Insider
Doyle John Brendan bought 10,000 shares
Chief Financial Officer @ $1.13 ($11.3K)
Price Targets
$3.50
+189.3% upside
Strong Buy
Current $1.21
Low $3.00
Median $3.50
High $4.00
4 analysts
$3.00
$4.00
Analyst Ratings
2Strong Buy
7Buy
1Hold
0Sell
0Strong Sell
Recent Analyst Actions
| Date | Firm | Action | Rating |
|---|---|---|---|
| Mar 27, 2026 | Chardan Capital | MAINTAIN | Buy → Buy |
Earnings Estimates
| Period | EPS Est. | Range | Growth | # |
|---|---|---|---|---|
| Current Q | $-0.06 ▲ +3.8% | $-0.07 — $-0.06 | 43% YoY | 4 |
| Next Q | $-0.07 ▼ -3.6% | $-0.08 — $-0.07 | -21% YoY | 4 |
| Current FY | $-0.32 ▼ -2.4% | $-0.44 — $-0.26 | -1% YoY | 4 |
| Next FY | $-0.28 | $-0.36 — $-0.19 | 14% YoY | 3 |
Latest Reports
NEUTRAL
8-K
4/10
Cognition Therapeutics filed an 8-K furnishing an investor presentation for the Jefferies Global Healthcare Conference.
Jun 4, 2026
NEUTRAL
Press
2/10
Cognition Therapeutics announced its CEO will present at the Jefferies Global Healthcare Conference (June 4) and H.C. Wa
Jun 1, 2026
NEUTRAL
8-K
5/10
Cognition Therapeutics reported Q1 2026 net loss of $4.6M ($0.05/share), narrower than the $8.5M loss in Q1 2025, driven
May 7, 2026
Top Institutional Holders
| Fund | Value | Move |
|---|---|---|
| VANGUARD CAPITAL MANAGEMENT LLC | $2.3M | — |
| RENAISSANCE TECHNOLOGIES LLC | $848.5K | ADD |
| BlackRock, Inc. | $735.5K | DOUBLED |
| VANGUARD FIDUCIARY TRUST CO | $352.4K | — |
| STATE STREET CORP | $238.8K | DOUBLED |
Recent Insider Trades
| Date | Insider | Type | Value |
|---|---|---|---|
| May 1, 2026 | Doyle John | F | $11.0K |
| Apr 16, 2026 | Doyle John | BUY | $11.3K |
| Apr 16, 2026 | Caggiano Anthony | BUY | $11.1K |
| Apr 16, 2026 | Ricciardi Lisa | BUY | $10.1K |
| Feb 4, 2026 | Doyle John | F | $27.7K |
Reddit Sentiment
77°▼
Bullish
Bearish
Neutral
Bullish
24 institutional holders with $4.8M total value (6,503,506 shares) as of 2026-Q1. Top holders: VANGUARD, RENAISSANCE, BlackRock,. Net selling activity: 1 institutions trimmed/exited vs 0 added.
Top Institutional Holders — 2026-Q1
| # | Fund | Shares | Value | % of Tracked | Last Move |
|---|---|---|---|---|---|
| 1 | VANGUARD CAPITAL MANAGEMENT LLC | 3,001,787 | $2.3M | 47.3% | — |
| 2 | RENAISSANCE TECHNOLOGIES LLC | 1,117,136 | $848.5K | 17.6% | ADD +35.9% |
| 3 | BlackRock, Inc. | 968,362 | $735.5K | 15.2% | DOUBLED +1160.4% |
| 4 | VANGUARD FIDUCIARY TRUST CO | 463,684 | $352.4K | 7.3% | — |
| 5 | STATE STREET CORP | 314,483 | $238.8K | 5.0% | DOUBLED +166.7% |
| 6 | CHARLES SCHWAB INVESTMENT MANAGEMENT INC | 84,940 | $64.5K | 1.3% | — |
| 7 | SUSQUEHANNA INTERNATIONAL GROUP, LLP | 80,663 | $61.3K | 1.3% | — |
| 8 | RAYMOND JAMES FINANCIAL INC | 47,500 | $36.1K | 0.7% | — |
| 9 | JONES FINANCIAL COMPANIES LLLP | 35,481 | $25.9K | 0.5% | — |
| 10 | GABELLI FUNDS LLC | 30,000 | $22.8K | 0.5% | — |
| 11 | MORGAN STANLEY | 27,873 | $21.2K | 0.4% | TRIM -70.1% |
| 12 | CITADEL ADVISORS LLC | 25,905 | $19.7K | 0.4% | — |
| 13 | HighTower Advisors, LLC | 24,000 | $18.2K | 0.4% | — |
| 14 | Vanguard Global Advisers, LLC | 23,641 | $18.0K | 0.4% | — |
| 15 | GAMCO INVESTORS, INC. ET AL | 20,000 | $15.2K | 0.3% | — |
| 16 | Rockefeller Capital Management L.P. | 19,231 | $14.6K | 0.3% | — |
| 17 | TWO SIGMA INVESTMENTS, LP | 19,229 | $14.6K | 0.3% | TRIM -50.8% |
| 18 | NORTHWESTERN MUTUAL WEALTH MANAGEMENT CO | 17,467 | $13.3K | 0.3% | — |
| 19 | Vanguard Personalized Indexing Management, LLC | 11,034 | $8.4K | 0.2% | — |
| 20 | Vestmark Advisory Solutions, Inc. | 10,040 | $7.6K | 0.2% | — |
Recent Position Changes
| Fund | Action | Prev Shares | Curr Shares | Change % | Value | Quarter |
|---|---|---|---|---|---|---|
| MORGAN STANLEY | TRIM | 93,328 | 27,873 | -70.1% | $21.2K | 2026-Q1 |
| RENAISSANCE TECHNOLOGIES LLC | ADD | 713,500 | 969,513 | +35.9% | $1.3M | 2025-Q4 |
| MORGAN STANLEY | DOUBLED | 32,690 | 93,328 | +185.5% | $126.0K | 2025-Q4 |
| TWO SIGMA INVESTMENTS, LP | TRIM | 96,991 | 47,729 | -50.8% | $64.4K | 2025-Q4 |
| WELLS FARGO & COMPANY/MN | TRIM | 4,000 | 3,000 | -25.0% | $4.0K | 2025-Q4 |
| VANGUARD GROUP INC | DOUBLED | 1,304,350 | 2,681,613 | +105.6% | $3.6M | 2025-Q3 |
| BlackRock, Inc. | DOUBLED | 76,855 | 968,699 | +1160.4% | $1.3M | 2025-Q3 |
| RENAISSANCE TECHNOLOGIES LLC | DOUBLED | 96,400 | 713,500 | +640.1% | $963.2K | 2025-Q3 |
| STATE STREET CORP | DOUBLED | 121,850 | 324,983 | +166.7% | $438.7K | 2025-Q3 |
| UBS Group AG | DOUBLED | 11,255 | 66,039 | +486.8% | $89.2K | 2025-Q3 |
| BANK OF AMERICA CORP /DE/ | DOUBLED | 495 | 5,595 | +1030.3% | $7.6K | 2025-Q3 |
| WELLS FARGO & COMPANY/MN | DOUBLED | 1,000 | 4,000 | +300.0% | $5.4K | 2025-Q3 |
| RENAISSANCE TECHNOLOGIES LLC | ADD | 55,700 | 96,400 | +73.1% | $29.9K | 2025-Q2 |
| UBS Group AG | DOUBLED | 1 | 11,255 | +1125400.0% | $3.5K | 2025-Q2 |
| UBS Group AG | NEAR_EXIT | 41,112 | 1 | -100.0% | — | 2025-Q1 |
| TWO SIGMA INVESTMENTS, LP | ADD | 53,691 | 82,544 | +53.7% | $34.7K | 2025-Q1 |
| RENAISSANCE TECHNOLOGIES LLC | TRIM | 91,100 | 55,700 | -38.9% | $23.4K | 2025-Q1 |
| MORGAN STANLEY | ADD | 16,873 | 31,069 | +84.1% | $13.1K | 2025-Q1 |
| BANK OF AMERICA CORP /DE/ | NEAR_EXIT | 5,290 | 305 | -94.2% | $128.00 | 2025-Q1 |
| COMMONWEALTH EQUITY SERVICES, LLC | TRIM | 90,665 | 41,665 | -54.0% | $18.00 | 2025-Q1 |
| STATE STREET CORP | ADD | 62,750 | 121,850 | +94.2% | $85.5K | 2024-Q4 |
| UBS Group AG | NEAR_EXIT | 197,859 | 41,112 | -79.2% | $28.8K | 2024-Q4 |
| MORGAN STANLEY | DOUBLED | 1,000 | 16,873 | +1587.3% | $11.8K | 2024-Q4 |
| FMR LLC | NEAR_EXIT | 101 | 1 | -99.0% | — | 2024-Q3 |
| MORGAN STANLEY | TRIM | 3,000 | 1,000 | -66.7% | $469.00 | 2024-Q3 |
3 unique insiders with 12 transactions. Net insider value: $32.5K ($32.5K bought, $0.00 sold).
Insider Transactions
| Date | Insider | Title | Type | Shares | Price | Value |
|---|---|---|---|---|---|---|
| May 1, 2026 | Doyle John Brendan | Chief Financial Officer | TAX W/H | 8,567 | $1.28 | $11.0K |
| Apr 16, 2026 | Doyle John Brendan | Chief Financial Officer | BUY | 10,000 | $1.13 | $11.3K |
| Apr 16, 2026 | Caggiano Anthony | Chief Medical Officer | BUY | 10,000 | $1.11 | $11.1K |
| Apr 16, 2026 | Ricciardi Lisa | CEO & President | BUY | 9,175 | $1.10 | $10.1K |
| Feb 4, 2026 | Doyle John Brendan | Chief Financial Officer | TAX W/H | 26,921 | $1.03 | $27.7K |
| Feb 4, 2026 | Caggiano Anthony | Chief Medical Officer | TAX W/H | 26,919 | $1.03 | $27.7K |
| Feb 4, 2026 | Ricciardi Lisa | CEO & President | TAX W/H | 51,704 | $1.03 | $53.3K |
| Feb 3, 2026 | Doyle John Brendan | Chief Financial Officer | AWARD | 200,000 | — | — |
| Feb 3, 2026 | Caggiano Anthony | Chief Medical Officer | AWARD | 400,000 | — | — |
| Feb 3, 2026 | Caggiano Anthony | Chief Medical Officer | TAX W/H | 11,488 | $1.12 | $12.9K |
| Feb 3, 2026 | Ricciardi Lisa | CEO & President | AWARD | 800,000 | — | — |
| Feb 3, 2026 | Ricciardi Lisa | CEO & President | TAX W/H | 26,036 | $1.12 | $29.2K |
3 SEC filing reports analyzed. Sentiment: 1 bullish, 0 bearish, 0 mixed, 2 neutral. Avg impact: 4.7/10.
NEUTRAL
8-K
4/10
Cognition Therapeutics filed an 8-K furnishing an investor presentation for the Jefferies Global Hea
Jun 4, 2026
NEUTRAL
8-K
5/10
Cognition Therapeutics reported Q1 2026 net loss of $4.6M ($0.05/share), narrower than the $8.5M los
May 7, 2026
BULLISH
CLUSTER
5/10
Two C-suite executives at Cognition Therapeutics (CGTX) — the CEO and Chief Medical Officer — purcha
Apr 20, 2026
NEUTRAL
2/10
Cognition Therapeutics announced its CEO will present at the Jefferies Global Healthcare Conference
Jun 1, 2026
BULLISH
6/10
Cognition Therapeutics held a productive FDA meeting on May 20, 2026, to discuss Phase 2 SHIMMER stu
May 21, 2026
NEUTRAL
3/10
Cognition Therapeutics announced a second philanthropic donation to extend its expanded access progr
May 14, 2026
NEUTRAL
5/10
Cognition Therapeutics (CGTX) reported financial results for Q4 and full year 2025, showing reduced
Mar 26, 2026
NEUTRAL
3/10
Cognition Therapeutics (CGTX) announced it will release Q4 and full-year 2025 financial results on M
Mar 23, 2026
BULLISH
8/10
Cognition Therapeutics presented Phase 2 SHIMMER study data showing zervimesine (CT1812) slowed decl
Mar 17, 2026
BULLISH
8/10
Cognition Therapeutics (CGTX) announced plans to advance zervimesine into a registrational developme
Mar 2, 2026
Current analyst consensus: Strong Buy (90% buy). Based on 10 analysts: 2 strong buy, 7 buy, 1 hold, 0 sell, 0 strong sell.
Analyst Price Targets
$3.50 mean target
+189.3% upside
Strong Buy (3.00)
$3.00 Low
$4.00 High
| Metric | Value |
|---|---|
| Current Price | $1.21 |
| Target Low | $3.00 |
| Target Mean | $3.50 |
| Target Median | $3.50 |
| Target High | $4.00 |
| # Analysts | 4 |
| Recommendation | Strong Buy (3.00) |
Earnings Estimates & Revisions
| Period | EPS Avg | EPS Low | EPS High | EPS Growth | 30d Rev. | Up/Down | Rev. Avg | Rev. Growth | Analysts |
|---|---|---|---|---|---|---|---|---|---|
| Current Q 2026-06-30 |
$-0.06 | $-0.07 | $-0.06 | 43.2% | +3.8% | 2↑ 1↓ | $0.0B | 0.0% | 4 |
| Next Q 2026-09-30 |
$-0.07 | $-0.08 | $-0.07 | -20.8% | -3.6% | 1↑ 1↓ | $0.0B | 0.0% | 4 |
| Current FY 2026-12-31 |
$-0.32 | $-0.44 | $-0.26 | -0.8% | -2.4% | 3↑ 1↓ | $0.0B | 0.0% | 4 |
| Next FY 2027-12-31 |
$-0.28 | $-0.36 | $-0.19 | 14.2% | — | 1↑ 1↓ | $0.0B | 0.0% | 3 |
Current Quarter EPS Revision History
| Timepoint | EPS Estimate | Change |
|---|---|---|
| Current | $-0.063 | |
| 7d ago | $-0.063 | |
| 30d ago | $-0.065 | +0.003 |
| 60d ago | $-0.085 | +0.023 |
| 90d ago | $-0.053 | -0.009 |
1 analyst firms have rated this stock: 0 upgrades, 0 downgrades, 0 initiations.
Individual Analyst Actions
| Date | Analyst Firm | Action | Previous Rating | New Rating |
|---|---|---|---|---|
| Mar 27, 2026 | Chardan Capital | MAINTAIN | Buy | Buy |
Monthly Consensus History
| Period | Strong Buy | Buy | Hold | Sell | Strong Sell | Buy % | Distribution |
|---|---|---|---|---|---|---|---|
| Jun 1, 2026 | 2 | 7 | 1 | 0 | 0 | 90% | |
| May 1, 2026 | 2 | 7 | 1 | 0 | 0 | 90% | |
| Apr 1, 2026 | 2 | 7 | 1 | 0 | 0 | 90% | |
| Mar 1, 2026 | 2 | 7 | 1 | 0 | 0 | 90% | |
| Feb 1, 2026 | 2 | 7 | 1 | 0 | 0 | 90% | |
| Jan 1, 2026 | 2 | 7 | 1 | 0 | 0 | 90% |
Strong BuyBuyHoldSellStrong Sell
No congressional trading data available for this ticker. Data is sourced from Senate and House financial disclosure filings.
77°
Bullish
Bearish
Neutral
Bullish
9 mentions
7 bullish
0 bearish
9 time periods
Reddit Sentiment History
| Date | Mentions | Sentiment | Bullish | Bearish | Threads |
|---|---|---|---|---|---|
| Jun 5, 2026 | 1 | 56° Neutral | 0 | 0 | 1 |
| Jun 4, 2026 | 1 | 56° Neutral | 0 | 0 | 1 |
| Jun 4, 2026 | 1 | 60° Warm | 1 | 0 | 1 |
| Jun 4, 2026 | 1 | 60° Warm | 1 | 0 | 1 |
| Mar 18, 2026 | 1 | 60° Warm | 1 | 0 | 1 |
| Mar 18, 2026 | 1 | 60° Warm | 1 | 0 | 1 |
| Mar 17, 2026 | 1 | 60° Warm | 1 | 0 | 1 |
| Mar 17, 2026 | 1 | 60° Warm | 1 | 0 | 1 |
| Feb 11, 2026 | 1 | 60° Warm | 1 | 0 | 1 |
Recent Reddit Threads
How come no one is talking about CGTX?
▲ 1
💬 1
⚡ 0.5
CGTX has very exciting news
▲ 2
💬 0
⚡ 0.5
CGTX the key is NPI
▲ 1
💬 1
⚡ 0.5
Jun 5, 2026
short_volume
Short Volume: CGTX — 56.9% short (0.3M / 0.6M)
Short: 342,694 | Exempt: 26,566 | TRF Vol: 602,379 | Short Ratio: 56.9% | Off-exchange volume (dark pool + OTC)
Jun 1, 2026
announcement
Cognition Therapeutics Participating in Upcoming Investor Conferences
<p>PURCHASE, N.Y., June 01, 2026 (GLOBE NEWSWIRE) -- <a href="https://www.globenewswire.com/Tracker?data=VBoBPZUlcl5bMXQWGDtH-aAI223sl75seqdyAwx2js_
May 21, 2026
fda
Cognition Therapeutics Completes Meeting with FDA for Zervimesine (CT1812) in Dementia with Lewy Bodies with Psychosis
<p align="center"><em>- Positive Discussion on Path Forward for Registrational Program -</em></p>
May 14, 2026
fda
Cognition Therapeutics Receives Second Philanthropic Donation to Extend Ongoing Expanded Access Program for Zervimesine (CT1812) in Dementia with Lewy Bodies
<p align="left">PURCHASE, N.Y., May 14, 2026 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc., (the “Company” or “Cognition”) (NASDAQ: CGTX), a clin
May 13, 2026
earnings_calendar
CGTX Q1 2026 Earnings Scheduled — 2026-05-13
May 7, 2026
earnings
Cognition Therapeutics Reports Financial Results for the First Quarter 2026 and Provides Business Update
<p align="center"><em>Meeting with FDA Division of Psychiatry scheduled for May 2026 expected to inform<br></em><em>registrational plans for zervimesi
May 5, 2026
earnings_calendar
CGTX Q1 2026 Earnings Scheduled — 2026-05-05
Apr 16, 2026
short_volume
Short Volume: CGTX — 58.5% short (0.5M / 0.8M)
Short: 479,441 | Exempt: 10,329 | TRF Vol: 819,849 | Short Ratio: 58.5% | Off-exchange volume (dark pool + OTC)
Apr 13, 2026
fda_pdufa
PDUFA: CGTX — zervimesine in Alzheimer's disease — 2026-04-13
FDA target action date 2026-04-13 for CGTX (COGNITION THERAPEUTICS INC). Drug: zervimesine. Indication: Alzheimer's disease. The company has aligned w
Apr 7, 2026
other
Cognition Therapeutics to Present at Needham Virtual Healthcare Conference
<p align="left">PURCHASE, N.Y., April 07, 2026 (GLOBE NEWSWIRE) -- <a href="https://www.globenewswire.com/Tracker?data=0MTCmC400jKiF1VLBfMPjcbcnDgE7
Apr 1, 2026
earnings_calendar
CGTX Q4 2025 Earnings After Market Close — 2026-04-01
Mar 31, 2026
other
Cognition Therapeutics CEO Issues Letter to Shareholders
<p align="center"><em>Advancing Zervimesine (CT1812) towards late-stage trials for </em><br><em>dementia with Lewy bodies (DLB) psychosis</em></p>
Mar 26, 2026
earnings
Cognition Therapeutics Reports Year End 2025 Financial Results and Provides Clinical Development Update
<p align="center"><em>-Advancing zervimesine clinical development in DLB psychosis – </em><br><em>- Meeting with FDA Division of Psychiatry expected b
Mar 26, 2026
earnings_calendar
CGTX Q4 2025 Earnings After Market Close — 2026-03-26
Mar 23, 2026
earnings
Cognition Therapeutics to Report Fourth Quarter and Year End 2025 Financial Results
Conference Call and Live Webcast Scheduled for March 26, 2026 <pre>Conference Call and Live Webcast Scheduled for March 26, 2026</pre>